SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
Biomarkers
/ blood
Blood Donors
/ statistics & numerical data
COVID-19
/ blood
COVID-19 Serological Testing
Canada
/ epidemiology
Cross-Sectional Studies
Female
Humans
Immunoglobulin G
/ blood
Logistic Models
Male
Middle Aged
Multivariate Analysis
Pandemics
Prevalence
SARS-CoV-2
/ immunology
Seroepidemiologic Studies
Young Adult
COVID-19
Canada
SARS-CoV-2 seroprevalence
blood donors
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
06
01
2021
received:
10
11
2020
accepted:
15
01
2021
pubmed:
3
2
2021
medline:
26
3
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Case detection underestimates the burden of the COVID-19 pandemic. Following the first COVID-19 wave, we estimated the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among blood donors across Canada. This serial cross-sectional study was conducted between May 9 and July 21, 2020 from blood donors donating at all Canadian Blood Services locations. We used the Abbott Architect assay to detect SARS-CoV-2 IgG antibodies from retention plasma. Seroprevalence was standardized to population-level demographics and assay characteristics were adjusted using the Rogan-Gladen equation. Results were stratified by region, age, ethnicity, ABO groups, and quantiles of material and social deprivation indices. Temporal trends were evaluated at 2-week intervals. Univariate and multivariate logistic regression compared SARS-CoV-2 reactive to non-reactive donors by sociodemographic variables. Overall 552/74642 donors, had detectable antibodies, adjusted seroprevalence was 7.0/1000 donors (95% CI; 6.3, 7.6). Prevalence was differential by geography, Ontario had the highest rate, 8.8/1000 donors (7.8, 9.8), compared to the Atlantic region 4.5/1000 donors (2.6, 6.4); adjusted odds ratio (aOR) 2.2 (1.5, 3.3). Donors that self-identified as an ethnic minority were more likely than white donors to be sero-reactive aOR 1.5 (1.2, 1.9). No temporal trends were observed. Worldwide, blood services have leveraged their operational capacity to inform public health. While >99% of Canadians did not show humoral evidence of past infection, we found regional variability and disparities by ethnicity. Seroprevalence studies will continue to play a pivotal role in evaluating public health policies by identifying trends and monitor disparities.
Sections du résumé
BACKGROUND
Case detection underestimates the burden of the COVID-19 pandemic. Following the first COVID-19 wave, we estimated the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among blood donors across Canada.
STUDY DESIGN AND METHODS
This serial cross-sectional study was conducted between May 9 and July 21, 2020 from blood donors donating at all Canadian Blood Services locations. We used the Abbott Architect assay to detect SARS-CoV-2 IgG antibodies from retention plasma. Seroprevalence was standardized to population-level demographics and assay characteristics were adjusted using the Rogan-Gladen equation. Results were stratified by region, age, ethnicity, ABO groups, and quantiles of material and social deprivation indices. Temporal trends were evaluated at 2-week intervals. Univariate and multivariate logistic regression compared SARS-CoV-2 reactive to non-reactive donors by sociodemographic variables.
RESULTS
Overall 552/74642 donors, had detectable antibodies, adjusted seroprevalence was 7.0/1000 donors (95% CI; 6.3, 7.6). Prevalence was differential by geography, Ontario had the highest rate, 8.8/1000 donors (7.8, 9.8), compared to the Atlantic region 4.5/1000 donors (2.6, 6.4); adjusted odds ratio (aOR) 2.2 (1.5, 3.3). Donors that self-identified as an ethnic minority were more likely than white donors to be sero-reactive aOR 1.5 (1.2, 1.9). No temporal trends were observed.
DISCUSSION
Worldwide, blood services have leveraged their operational capacity to inform public health. While >99% of Canadians did not show humoral evidence of past infection, we found regional variability and disparities by ethnicity. Seroprevalence studies will continue to play a pivotal role in evaluating public health policies by identifying trends and monitor disparities.
Identifiants
pubmed: 33527398
doi: 10.1111/trf.16296
pmc: PMC8013879
doi:
Substances chimiques
Antibodies, Viral
0
Biomarkers
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
862-872Subventions
Organisme : Government of Canada
Informations de copyright
© 2021 AABB.
Références
Emerg Infect Dis. 2007 Oct;13(10):1562-4
pubmed: 18258008
J Infect. 2020 Jul;81(1):147-178
pubmed: 32209385
MMWR Morb Mortal Wkly Rep. 2020 Jun 05;69(22):680-684
pubmed: 32497028
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Transfusion. 2011 Sep;51(9):1883-5
pubmed: 21790637
Clin Infect Dis. 2021 Jan 27;72(2):249-253
pubmed: 33501969
Int J Antimicrob Agents. 2020 Jun;55(6):106006
pubmed: 32371096
Pathology. 2020 Dec;52(7):770-777
pubmed: 33092816
Nat Rev Immunol. 2020 Oct;20(10):583-584
pubmed: 32908300
Health Aff (Millwood). 2002 Mar-Apr;21(2):60-76
pubmed: 11900187
Prev Vet Med. 2014 Jan 1;113(1):13-22
pubmed: 24416798
Lancet. 2016 Aug 13;388(10045):728-30
pubmed: 27059886
Am J Respir Crit Care Med. 2020 Oct 1;202(7):943-949
pubmed: 32677842
Transfusion. 2021 Mar;61(3):862-872
pubmed: 33527398
Can J Public Health. 2012 Apr 30;103(8 Suppl 2):S17-22
pubmed: 23618066
Emerg Infect Dis. 2020 Sep;26(9):1978-1986
pubmed: 32544053
Blood. 2020 Nov 26;136(22):2588-2591
pubmed: 33001206
Nat Commun. 2020 Nov 12;11(1):5744
pubmed: 33184284
BMJ. 2020 Sep 3;370:m3364
pubmed: 32883673
Nat Commun. 2020 Sep 17;11(1):4698
pubmed: 32943630
Vox Sang. 2021 Mar;116(3):296-304
pubmed: 33165917
Clin Infect Dis. 2021 Feb 16;72(4):703-706
pubmed: 32562416
JAMA. 2020 Aug 25;324(8):743-744
pubmed: 32790824
Am J Prev Med. 2017 Jan;52(1S1):S5-S12
pubmed: 27989293
Cell Discov. 2020 Sep 15;6:64
pubmed: 32983570
JAMA. 2020 Sep 14;:
pubmed: 32926078
Transfusion. 2020 Dec;60(12):3046-3054
pubmed: 32798237
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Euro Surveill. 2020 Jul;25(28):
pubmed: 32700672
Eur J Public Health. 2020 Aug 1;30(4):617-618
pubmed: 32638998
JAMA. 2020 May 19;323(19):1891-1892
pubmed: 32293639
Chronic Dis Can. 2009;29(4):178-91
pubmed: 19804682